Tracer library / [18F]AlF-NOTA-octreotide

[18F]AlF-NOTA-octreotide

Also written as [18F]AlF-NOTA-Octreotide; [F-18]AlF-NOTA-Octreotide
Radionuclide
F-18 t½ 109.77 min
Modality
PET
Production route
—
Stage
—
Syntheses indexed
2
Neuroendocrine neoplasms

What it is

Compound class
NOTA-conjugated somatostatin analog (octreotide) radiolabeled via Al18F
Target / mechanism
Binds somatostatin receptor subtype 2 (SSTR2) PMID 31997090
Clinical application
PET/CT imaging of somatostatin receptor expression in neuroendocrine neoplasms PMID 42014536
Theranostic pair
—

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
FASTlab 2
GE HealthCare
vendor cassetteSPE42 ± 1.5%>95%NOTA-octreotide…NOTA-octreotide (NOTA-D-phe-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Throl)
WuXi AppTec
42014536
2026 EJNMMI Radiopharm Chem
GE Fastlab 2 automated synthesis module (General Electric Healthcare) - a radiochemical yield (RCY) of 42 ± 1.5%
AllinOne (AiO)
Trasis
vendor cassetteSPE26.1 ± 3.6%
decay-corrected
96.3 ± 0.2%NOTA-octreotide trifluoracetate
ABX
31997090
2020 EJNMMI Radiopharm Chem
[18F]AlF-NOTA-octreotide was synthesized in an AllInOne® synthesis module (Trasis, Ans, Belgium). - a radiochemical yield of 26.1 ± 3.6% (dc)

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

  1. [18F]MFBG PET/CT is an effective and preferable imaging modality for neuroblastoma in a prospective comparison with SSTR PET.
    2026 · Eur J Nucl Med Mol Imaging · Prospective
  2. Meningioma theranostics: a retrospective analysis of somatostatin receptor PET/CT imaging and peptide receptor radionuclide therapy.
    2026 · Eur J Nucl Med Mol Imaging · Retrospective
  3. ¹⁸F-AlF-NOTA-octreotide PET/CT in high-grade G3 neuroendocrine tumors and neuroendocrine carcinomas: diagnostic performance and complementarity with ¹⁸F-FDG PET/CT.
    2026 · Eur J Nucl Med Mol Imaging · Retrospective

Precursor

Common precursor
—
Suppliers seen in the literature
—
Cited suppliers in indexed syntheses
ABX, WuXi AppTec
Typical final purification
—

Need this precursor?We can point you to suppliers for [18F]AlF-NOTA-octreotide, or handle the enquiry for you.

Get in touch

Quality control Preliminary - inferred from compound class

Ph. Eur. monograph
not verified No Ph. Eur. check is recorded for this entry.
USP monograph
not verified No USP check is recorded for this entry.
AppearancepHRCP HPLCRCP TLCHPLC UVRadionuclidic (HPGe)Half-lifeActivityEndotoxins (LAL)SterilityFilter integrityMolar activity
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); receptor ligand with a saturable target -> molar activity (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)

Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived

Setting up quality control?We can help you scope the equipment needed to release [18F]AlF-NOTA-octreotide.

Get in touch

Notes

Added from reverse module search (stage 6); 7 article(s) with F-18. Compound class inferred from precursor name (not stated outright) -- PMID 42014536: 'NOTA-octreotide (NOTA-D-phe-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Throl)'.
Ask a question